BioRestorative Therapies 11/12/2024 Earnings Report $1.55 +0.10 (+6.90%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast BioRestorative Therapies EPS ResultsActual EPS-$0.13Consensus EPS -$0.35Beat/MissBeat by +$0.22One Year Ago EPSN/ABioRestorative Therapies Revenue ResultsActual Revenue$0.23 millionExpected Revenue$0.30 millionBeat/MissMissed by -$70.00 thousandYoY Revenue GrowthN/ABioRestorative Therapies Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call ResourcesBRTX Earnings History Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> BioRestorative Therapies Earnings HeadlinesBioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease ProgramDecember 5, 2024 | globenewswire.comBioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.com⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.December 22, 2024 | Behind the Markets (Ad)BioRestorative Therapies to Announce Phase 2 Trial DataNovember 7, 2024 | markets.businessinsider.comBioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research SymposiumNovember 6, 2024 | markets.businessinsider.comBioRestorative Therapies Receives Expanded Tissue License from New York State Department of HealthNovember 5, 2024 | globenewswire.comSee More BioRestorative Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioRestorative Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioRestorative Therapies and other key companies, straight to your email. Email Address About BioRestorative TherapiesBioRestorative Therapies (NASDAQ:BRTX), a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.View BioRestorative Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
